Brucellosis laboratory findings: Difference between revisions

	Brucellosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Brucellosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Principles of diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X-Ray
CT Scan
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Brucellosis laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Brucellosis laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Brucellosis laboratory findings
CDC on Brucellosis laboratory findings
Brucellosis laboratory findings in the news
Blogs on Brucellosis laboratory findings
Directions to Hospitals Treating Brucellosis
Risk calculators and risk factors for Brucellosis laboratory findings

VisualWikitext

Latest revision as of 20:44, 29 July 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Danitza Lukac Vishal Devarkonda, M.B.B.S [3]

Overview

The diagnosis of brucellosis can be confirmed by either a positive bacterial culture or a positive titer of anti-brucella antibodies on serological testing.

Laboratory Findings

Laboratory findings of brucellosis include the following:^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]^[10]^[11]^[12]^[13]

Laboratory findings in Brucellosis
Blood	Complete blood count	Complete Blood Count may reveal: Mild leukopenia Mild anemia Relative lymphocytosis Thrombocytopenia
	ESR	Normal or raised
	CRP	Normal or raised
	Liver function test	Liver function test may reveal: Mild increase in hepatic enzymes Mild increase in bilirubin
	Culture	The isolation and identification of Brucella can confirm a diagnosis of brucellosis. Brucella is most commonly isolated from blood cultures (blood cultures are positive between the 7th and 21st day) It can also, however, be isolated from: Bone marrow (Gold standard test) Cerebrospinal fluid Wounds Purulent discharge Joint fluid^[14]^[1]
	Serological tests	Serological Tests There are two types of serological tests, based on: Antibody production against lipopolysaccharide Antibody production against other bacterial antigens For a diagnosis to be made using serology, two serum samples are required: The first serum sample should be taken when a person is acutely ill (≤7 days after symptom onset) The second serum sample should be drawn 2-4 weeks later to check for a rise in antibodies (a fourfold or greater rise in antibodies would bean an individual is positive for brucellosis). If submission of paired sera is not possible, a probable diagnosis can be made with a single serum sample. Brucella microagglutination test (BMAT) A modified version of the serum (tube) agglutination test (SAT), that can detect antibodies to Brucella species: abortus, melitensis or suis. There is no serological test available to detect antibodies to B. canis. An agglutination titre greater than 1:160 is considered significant in nonendemic areas. An agglutination titre greater than 1:320 is considered significant in endemic areas. Due to the similarity of the O polysaccharide of Brucella to that of various other gram-negative bacteria (e.g. Francisella tularensis, Escherichia coli, Salmonella urbana, Yersinia enterocolitica, Vibrio cholerae, and Stenotrophomonas maltophilia) the appearance of cross-reactions of class M immunoglobulins may occur. False-negative SAT may be caused by the presence of blocking antibodies (the prozone phenomenon) in the α2-globulin (IgA) and in the α-globulin (IgG) fractions. Serology is not currently available to monitor persons for RB51 vaccine exposure or for Brucella canis exposure. Rose Bengal Rose bengal has a positive predictive value is approximately 99% for patients with acute and chronic brucellosis. Rose bengal measures IgM and IgG antibodies. 2-mercaptoethanol (2-ME) 2-ME measures IgG antibodies Antihuman globulin (Coombs) Used in chronic brucellosis patients with negative seroagglutination because they have IgG non-agglutinating antibodies. Indirect enzyme linked immunosorbent assay (ELISA) ELISA typically uses cytoplasmic proteins as antigens. ELISA measures IgM, IgG, and IgA with better sensitivity and specificity than the SAT in most recent comparative studies. Dipstick assays New and promising, based on the binding of Brucella IgM antibodies, and found to be simple, accurate and rapid. Brucellacapt test A single-step immunocapture assay for the detection of total anti-Brucella antibodies, is an increasingly used adjunctive test when resources permit.
	Molecular tests	PCR PCR is a fast and specific diagnostic tool to confirm the diagnosis of brucellosis Many varieties of PCR have been developed (e.g. nested PCR, realtime PCR and PCR-ELISA) and found to have superior specificity and sensitivity in detecting both primary infection and relapse after treatment. Unfortunately, these have yet to be standardized for routine use, and some centres have reported persistent PCR positivity after clinically successful treatment, fuelling the controversy about the existence of prolonged chronic brucellosis.^[14]^[15]^[16]^[17]

Tissue Biopsy

Liver and lymph node biopsy may reveal non-caseating granuloma.^[2]^[4]

CSF analysis

CSF analysis may reveal lymphocytosis and low glucose level.^[2]^[4]

Synovial fluid analysis

Synovial fluid analysis may reveal lymphocytic predominate with granulocyte count which does not generally exceed 15,000 cells/microL and low glucose levels.^[2]^[4]

Gallery

Brucella abortus bacteria grown on a medium of sheep’s blood agar (SBA) 72hrs. From Public Health Image Library (PHIL). ^[18]
Brucella abortus bacteria grown on a medium of sheep’s blood agar (SBA) 72hrs. From Public Health Image Library (PHIL). ^[18]
Brucella abortus bacteria grown on a medium of sheep’s blood agar (SBA) 72hrs. From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria grown on chocolate medium 72hrs. From Public Health Image Library (PHIL). ^[18]
Brucella sis bacteria grown on chocolate medium 72hrs. From Public Health Image Library (PHIL). ^[18]
Brucella bacteria grown on MacConkey agar (MAC) medium 24hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on chocolate agar medium 48hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on SBA 24hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on SBA 72hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on SBA 48hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on Thayer-Martin (TM) agar medium 48hrs (10x mag). From Public Health Image Library (PHIL). ^[18]
Brucella suis bacteria cultured on chocolate agar medium 24hrs (10x mag). From Public Health Image Library (PHIL). ^[18]

References

↑ ^1.0 ^1.1 Brucellosis. CDC. http://www.cdc.gov/brucellosis/clinicians/bacterial-isolation.html. Accessed on February 4, 2016
↑ ^2.0 ^2.1 ^2.2 ^2.3 Brucellosis "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 9th, 2017
↑ Colmenero JD, Reguera JM, Martos F, Sánchez-De-Mora D, Delgado M, Causse M; et al. (1996). "Complications associated with Brucella melitensis infection: a study of 530 cases.". Medicine (Baltimore). 75 (4): 195–211. PMID 8699960
↑ ^4.0 ^4.1 ^4.2 ^4.3 Mantur BG, Amarnath SK, Shinde RS (2007). "Review of clinical and laboratory features of human brucellosis.". Indian J Med Microbiol. 25 (3): 188–202. PMID 17901634
↑ Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis.". N Engl J Med. 352 (22): 2325–36. PMID 15930423.
↑ Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J (2012). "Clinical manifestations of human brucellosis: a systematic review and meta-analysis". PLoS Negl Trop Dis. 6 (12): e1929. doi:10.1371/journal.pntd.0001929. PMC 3516581. PMID 23236528.
↑ Young EJ (1995). "Brucellosis: current epidemiology, diagnosis, and management.". Curr Clin Top Infect Dis. 15: 115–28. PMID 7546364
↑ Aygen B, Doganay M, Sumerkan B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.
↑ Zamani A, Kooraki S, Mohazab RA, Zamani N, Matloob R, Hayatbakhsh MR; et al. (2011). "Epidemiological and clinical features of Brucella arthritis in 24 children". Ann Saudi Med. 31 (3): 270–3. doi:10.4103/0256-4947.81543. PMC 3119967. PMID 21623056.
↑ Mousa AM, Bahar RH, Araj GF, Koshy TS, Muhtaseb SA, al-Mudallal DS; et al. (1990). "Neurological complications of brucella spondylitis.". Acta Neurol Scand. 81 (1): 16–23. PMID 2330811
↑ Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E (2003). "Brucellosis and the respiratory system.". Clin Infect Dis. 37 (7): e95–9. PMID 13130417. doi:10.1086/378125
↑ Herrick JA, Lederman RJ, Sullivan B, et al. Brucella arteritis: clinical manifestations, treatment, and prognosis. Lancet Infect Dis 2014; 14:520.
↑ Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME; et al. (2007). "Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations". PLoS Med. 4 (12): e317. doi:10.1371/journal.pmed.0040317. PMC 2222927. PMID 18162038.
↑ ^14.0 ^14.1 Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis". N Engl J Med. 352 (22): 2325–36. doi:10.1056/NEJMra050570. PMID 15930423.
↑ Brucellosis. CDC. http://www.cdc.gov/brucellosis/transmission/index.html. Accessed on February 1, 2016
↑ Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on January 29, 2016
↑ Brucelosis. Wikipedia. https://es.wikipedia.org/wiki/Brucelosis. Accessed on February 2, 2016
↑ ^18.00 ^18.01 ^18.02 ^18.03 ^18.04 ^18.05 ^18.06 ^18.07 ^18.08 ^18.09 ^18.10 ^18.11 "Public Health Image Library (PHIL)".

Template:WH Template:WS

[g-1] 1.0 ^1.1 Brucellosis. CDC. http://www.cdc.gov/brucellosis/clinicians/bacterial-isolation.html. Accessed on February 4, 2016

[:0-2] 2.0 ^2.1 ^2.2 ^2.3 Brucellosis "Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson, Joseph Loscalzo"Harrison's Principles of Internal Medicine, 19e Accessed on December 9th, 2017

[3] Colmenero JD, Reguera JM, Martos F, Sánchez-De-Mora D, Delgado M, Causse M; et al. (1996). "Complications associated with Brucella melitensis infection: a study of 530 cases.". Medicine (Baltimore). 75 (4): 195–211. PMID 8699960

[:1-4] 4.0 ^4.1 ^4.2 ^4.3 Mantur BG, Amarnath SK, Shinde RS (2007). "Review of clinical and laboratory features of human brucellosis.". Indian J Med Microbiol. 25 (3): 188–202. PMID 17901634

[5] Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis.". N Engl J Med. 352 (22): 2325–36. PMID 15930423.

[pmid23236528-6] Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J (2012). "Clinical manifestations of human brucellosis: a systematic review and meta-analysis". PLoS Negl Trop Dis. 6 (12): e1929. doi:10.1371/journal.pntd.0001929. PMC 3516581. PMID 23236528.

[7] Young EJ (1995). "Brucellosis: current epidemiology, diagnosis, and management.". Curr Clin Top Infect Dis. 15: 115–28. PMID 7546364

[8] Aygen B, Doganay M, Sumerkan B, et al. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med Malad Infect 2002; 32:485.

[pmid21623056-9] Zamani A, Kooraki S, Mohazab RA, Zamani N, Matloob R, Hayatbakhsh MR; et al. (2011). "Epidemiological and clinical features of Brucella arthritis in 24 children". Ann Saudi Med. 31 (3): 270–3. doi:10.4103/0256-4947.81543. PMC 3119967. PMID 21623056.

[10] Mousa AM, Bahar RH, Araj GF, Koshy TS, Muhtaseb SA, al-Mudallal DS; et al. (1990). "Neurological complications of brucella spondylitis.". Acta Neurol Scand. 81 (1): 16–23. PMID 2330811

[11] Pappas G, Bosilkovski M, Akritidis N, Mastora M, Krteva L, Tsianos E (2003). "Brucellosis and the respiratory system.". Clin Infect Dis. 37 (7): e95–9. PMID 13130417. doi:10.1086/378125

[12] Herrick JA, Lederman RJ, Sullivan B, et al. Brucella arteritis: clinical manifestations, treatment, and prognosis. Lancet Infect Dis 2014; 14:520.

[pmid18162038-13] Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME; et al. (2007). "Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations". PLoS Med. 4 (12): e317. doi:10.1371/journal.pmed.0040317. PMC 2222927. PMID 18162038.

[pmid15930423-14] 14.0 ^14.1 Pappas G, Akritidis N, Bosilkovski M, Tsianos E (2005). "Brucellosis". N Engl J Med. 352 (22): 2325–36. doi:10.1056/NEJMra050570. PMID 15930423.

[b-15] Brucellosis. CDC. http://www.cdc.gov/brucellosis/transmission/index.html. Accessed on February 1, 2016

[a-16] Brucellosis. Wikipedia. https://en.wikipedia.org/wiki/Brucellosis. Accessed on January 29, 2016

[aa-17] Brucelosis. Wikipedia. https://es.wikipedia.org/wiki/Brucelosis. Accessed on February 2, 2016

[PHIL-18] 18.00 ^18.01 ^18.02 ^18.03 ^18.04 ^18.05 ^18.06 ^18.07 ^18.08 ^18.09 ^18.10 ^18.11 "Public Health Image Library (PHIL)".

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

@@ Line 119: / Line 119: @@
 ==References==
 {{reflist|2}}
-[[Category:Disease]]
+{{WH}}
-[[Category:Primary care]]
+{{WS}}
-[[Category:Up-To-Date]]
-[[Category:Pulmonology]]
+[[Category:Disease]]
+[[Category:Up-To-Date]]
+[[Category:Pulmonology]]
 [[Category:Hepatology]]
 [[Category:Rheumatology]]
 [[Category:Nephrology]]
+[[Category:Emergency medicine]]
-{{WH}}
+[[Category:Infectious disease]]
-{{WS}}